Safety and efficacy of adjunctive lacosamide in Chinese and Japanese adults with epilepsy and focal seizures: A long-term, open-label extension of a randomized, controlled trial

•Open-label extension trial of adjunctive lacosamide in Chinese and Japanese people with epilepsy (PWE).•67.9 % and 52.0 % of PWE received lacosamide for >24 and >36 months, respectively.•86.7 % had a treatment-emergent adverse event (TEAE); 10.4 % discontinued due to a TEAE.•The median reduction in focal seizure frequency per 28 days from Baseline was 57.1 %.•Adjunctive lacosamide was well tolerated, with good safety profile up to 400 mg/day.